Moreover, NGF exerts a protective and healing effect on the corneal tissue that led to the approval of recombinant human NGF (Oxervate, Dompé Farmaceutici SpA, Milan, Italy) for the topical treatment of neurotrophic keratopathy, a rare corneal disorder induced by trigeminal nerve impairments which causes epithelial damage and corneal ulcerations [6]. Here, NGF is linked to corneal infection.